1-3 of 3
Andrew Spencer, MBBS, MD FRACP, FRCPA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Krystal Bergin, Flora Yuen, BBiomedSc, Craig Thomas Wallington-Beddoe, BSc, MBBS, PhD FRACP, FRCPA, Anna Kalff, MBBS, Shreerang Sirdesai, MBBS, FRACP, FRCPA, John Reynolds, PhD, Andrew Spencer, MBBS, MD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 3265.
https://doi.org/10.1182/blood-2018-99-118172
Published: 2018
Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 1986.
https://doi.org/10.1182/blood-2018-99-118231
Published: 2018
Journal Articles

CRISPR-Cas9 Mediated CD45 Knockout Inactivates Src Family Kinases and Impairs Cell Migration in Multiple Myeloma

Wing Yu Man, BSc, Tiffany Khong, BSc, PhD, Andrew Spencer, MBBS, MD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 1907.
https://doi.org/10.1182/blood-2018-99-117532
Published: 2018